YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications - adolescent hidradenitis suppurativa (HS) and pediatric uveitis (UV), in the ...

Upadacitinib and secukinumab for PsA offers comparable improvements in skin and joint symptoms, but adalimumab offers superior pain relief.

Topicals are often the first-line treatment for psoriasis, but as the condition progresses, you may need to consider systemic treatments to manage your symptoms. Here’s what to know about your options ...

Treatment with guselkumab led to improvements in disease activity over 1 year among patients with PsA and showed a high retention rate.

Jenifer Soung, MD, fo Southern California Dermatology, discussed how glucagon-like peptide-1 receptor agonists aid in treating patients with psoriatic disease. Captions are auto-generated.

Still given JNJ has most of the rights to market and sell icontrokinra, is there any pressing need to complete a full, ...

Soung also spoke at the 2025 Skin of Color Update, addressing multidisciplinary approaches to treating comorbidities in ...

Adults with psoriatic arthritis saw early improvements in their symptoms and key health-related quality-of-life measures with ...

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving ...

Patients with PsA have a higher prevalence of MetS compared with members of the general population and individuals with other inflammatory arthropathies.

Dr Philip Mease explores how modern imaging tools are reshaping the understanding of joint damage and progression in ...